Variability of the bioavailability of cyclosporin: Benefit of the Neoral® formulation;VARIABILITE DE LA BIODISPONIBILITE DE LA CICLOSPORINE: AVANTAGE DE LA FORMULATION NEORAL

Therapie

Volumn 52, Issue 4, 1997, Pages 353-357

  Humbert, H ^a  

^a NOVARTIS PHARMA K K   (Japan)

Author keywords

Cyclosporin; Oral route; Pharmacokinetic; Variability

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

BIOAVAILABILITY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; CHEMISTRY; KIDNEY TRANSPLANTATION; POSTOPERATIVE CARE; REVIEW;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE CARE;

EID: 0030873525     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Kahan BD, Shaw LM, Holt D et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporinc. Clin Chem 1990; 36: 1510-1516.
2. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631-644.
3. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
4. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokin 1986; 11: 107-132.
5. Vonderscher J, Meinzer A. Rationale for the development of Sandimmun Neoral. Transplant Proc 1994; 26: 2925-2927.
6. Kovarik JM, Mueller EA, Van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-663.
7. Girault D, Haloun A, Viard L et al. Sandimmun Neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis. Transplant proc 1995; 27: 2488-2490.
8. Kovarik JM, Mueller EA, Van Bree JB et al. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232-237.
9. Kovarik JM, Kallay Z, Mueller EA et al. Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. Transpl Int 1995; 8: 335-339.
10. Wahlberg J, Wilczek HE, Fauchald P et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60: 648-652.
11. Van der Pijl JW, Srivastava N, Denouël J et al. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. Transplantation 1996; 62: 456-462.
12. Tan KKC, Trull AK, Uttridge JA, Wallwork J. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 1995; 48: 285-289.
13. Mueller EA, Kovarik JM, Van Bree JB et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151-155.
14. Kahan BD, Dunn J, Fitts C et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-511.
15. Trull AK, Tan KKC, Tan L et al. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995; 39: 627-631.
16. Altraif I, Levy G, Grant D and the Ontario Liver Transplant Study Group. Pharmacokinetic studies of Sandimmun Neoral in liver transplant recipients. Hepatology 1993; 18 (4 Pt 2): 75A.
17. Farges O, Haddad N, Girault D et al. Conversion from cyclosporine Sandimmun to cyclosporine Neoral in liver transplant patients with cholestasis or external biliary drainage. Transplant Proc 1995; 27: 2506-2507.
18. Kahan BD. Neoral® addresses two limitations of existing cyclosporine formulations: limited and variable drug absorption. In: Neoral®: the new microemulsion formulation of cyclosporine, Cedars Knoll, NJ: World Medical Press 1995; special report: 12-18.
19. Niese D. and the International Sandimmun Neoral Study Group. A double-blind randomized study of Sandimmun® Neoral versus, Sandimmun in new renal transplant recipients: results after 12 months. Transpl Proc 1995; 27: 1849-1856.
20. Mueller EA, Kovarik JM, Van Bree JB et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301-304.
21. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun® Neoral, in renal transplant patients. Transpl Int 1994; 7 (Suppl 1), S263-S266.
22. Fiocchi R, Mamprin F, Gamba A et al. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 1994; 26: 2994-2995.
23. Freeman D, Grant D, Levy G et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213-216.
24. Van den Borne BEEM, Landewé RBM, Goei The HS et al. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. Br J Clin Pharmacal 1995; 39: 172-175.
25. Elder CA, Moore M, Chang CT et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995; 35: 865-875.
26. Chawla M, Ali M, Marks R. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis. Br J Dermatol 1996; 135 (Suppl 48): 9-14.
27. Pollard S. Utilisation de Néoral chez des transplantés rénaux de novo: résultats à 3 mois. In: Johnson RWG ed. Transplantation 96: maximizing patient benefit in transplantation, International Congress and Symposium Series no 217, Royal Society of Medicine Press Ltd, 1996; 31-37.
28. Hemming AW, Greig PD, Cattral MS et al. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation. Transplantation 1996; 62: 1798-1802.
29. Keown P, Lawen JG, Landsberg D. Economic analysis of Sandimmun® Neoral in Canada in stable renal transplant patients. Transpl Proc 1995; 27: 1845-1848.